Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results
A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.
A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.